Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression-Reference-Cited by-同舟云学术

Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression

Published:2017-08 Issue:8 Volume:27 Page:714-731
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Ricken Roland,Ulrich Sven,Schlattmann Peter,Adli Mazda

Funder

German Ministry of Education and Research (BMBF)

German Science Foundation (DFG)

European Union

Publisher

Elsevier BV

Reference155 articles.

1. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study;Adli;J. Clin. Psychiatry,2002

2. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression;Adli;Pharmacopsychiatry,2008

3. Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II?;Akiskal;J. Affect. Disord.,2005

4. American Psychiatric Association (APA), 2010. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Retrieved from: 〈http://psychiatryonline.org/guidelines〉 (March 16th 2015).

5. High dose tranylcypromine therapy for refractory depression;Amsterdam;Pharmacopsychiatry,1989

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of antidepressants on weight: mechanisms, clinical effects, and management strategies;Russian Medicine;2025-06-11

2. Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications;Current Obesity Reports;2025-01-03

3. Epigenetic-modifying agents: The potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-12

4. Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression;Acta Psychiatrica Scandinavica;2024-09-03

5. Nanocarrier drug delivery system: promising platform for targeted depression therapy;Frontiers in Pharmacology;2024-07-25